Fig. 3From: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italya EFS in induction responders; b OS in induction responders; c OS in induction non-respondersBack to article page